BrainsWay $BWAY

Health Care · NASDAQ

Israel
$8.48
-0.25 (-2.86%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 30, 2026, the first target we tracked for BWAY.

BrainsWay (BWAY) is trading down at $8.48 (-2.86%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: April 17, 2019 · $11.00 offering · NASDAQ

Analyst price targets on BWAY

One firm's current price target on BrainsWay: $19 — 124% above the current $8.48. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 30, 2026 FirmH.C. Wainwright RatingBuy · maintains Targetat $11.4 · $19 +67% Horizonby Oct 2027 stated StatusOpen

Entry price $11.4, the close nearest Oct 30, 2026, when the target was reported; the target is +67% from it.

Horizon H.C. Wainwright set the horizon itself: Oct 2027.

Scoring Open: judged on the close on Oct 30, 2027.

Source Brainsway stock price target maintained at $19 by H.C. Wainwright Investing.com · Oct 30, 2026 · opens the publisher's site
H.C. Wainwright reiterated a Buy rating and $19.00 price target on Brainsway

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

BrainsWay revenue & net income history (FY2017–FY2024)

RevenueNet incomeNet margin (right axis, %)
$41.0M$13.8M−$13.3MFY2017 revenue: $11.1MFY2017 net income: −$7.05M · Net margin −63.3%'17FY2018 revenue: $16.4MFY2018 net income: −$6.48M · Net margin −39.5%'18FY2019 revenue: $23.1MFY2019 net income: −$10.3M · Net margin −44.7%'19FY2020 revenue: $22.1MFY2020 net income: −$5.38M · Net margin −24.4%'20FY2021 revenue: $29.7MFY2021 net income: −$6.46M · Net margin −21.8%'21FY2022 revenue: $27.2MFY2022 net income: −$13.3M · Net margin −49.1%'22FY2023 revenue: $31.8MFY2023 net income: −$4.20M · Net margin −13.2%'23FY2024 revenue: $41.0MFY2024 net income: $2.92M · Net margin 7.1%'24−6.5%0%10%20%FY2017 net margin: −63.3% (off the scale, which stops at −6.5%)FY2018 net margin: −39.5% (off the scale, which stops at −6.5%)FY2019 net margin: −44.7% (off the scale, which stops at −6.5%)FY2020 net margin: −24.4% (off the scale, which stops at −6.5%)FY2021 net margin: −21.8% (off the scale, which stops at −6.5%)FY2022 net margin: −49.1% (off the scale, which stops at −6.5%)FY2023 net margin: −13.2% (off the scale, which stops at −6.5%)FY2024 net margin: 7.1%
BrainsWay annual financial statements
FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024
Income statement
Revenue$11.1M$16.4M$23.1M$22.1M$29.7M$27.2M$31.8M$41.0M
Growth (year over year)—+47.1%+40.9%−4.5%+34.5%−8.4%+17.0%+29.0%
Gross profit$8.55M$12.8M$18.0M$17.0M$23.1M$20.0M$23.5M$30.6M
Gross margin76.7%78.1%77.8%77.1%77.7%73.8%73.9%74.6%
Operating income−$6.61M−$5.11M−$8.48M−$4.83M−$5.00M−$12.7M−$4.96M$1.39M
Operating margin−59.3%−31.2%−36.7%−21.9%−16.9%−46.7%−15.6%3.4%
Net income−$7.05M−$6.48M−$10.3M−$5.38M−$6.46M−$13.3M−$4.20M$2.92M
Net margin−63.3%−39.5%−44.7%−24.4%−21.8%−49.1%−13.2%7.1%
EPS (diluted)−$0.48−$0.39−$0.50−$0.24−$0.21−$0.40−$0.13$0.05
Balance sheet
Cash and equivalents$14.5M$8.97M$21.7M$17.0M$16.9M$47.6M$10.5M$69.3M
Total assets—$23.6M$38.7M$34.0M$75.7M$64.5M$63.0M$94.3M
Total liabilities—$16.6M$14.5M$14.4M$18.4M$19.1M$21.4M$32.0M
Shareholders' equity$12.7M$6.95M$24.2M$19.6M$57.3M$45.4M$41.6M$62.3M
Cash flow
Operating cash flow−$3.47M−$3.77M−$7.24M−$1.44M$884.0K−$9.76M$1.28M$10.3M
Capital expenditure$985.0K$1.97M$3.31M$2.47M$2.24M———
Free cash flow−$4.45M−$5.75M−$10.6M−$3.91M−$1.35M———

From BrainsWay's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

BrainsWay in the news

Nov 10, 2026 GlobeNewswire BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights
Oct 30, 2026 Investing.com Brainsway stock price target maintained at $19 by H.C. Wainwright Target

About BrainsWay

Headquarters
Jerusalem, Israel From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →